Both increased graft rejection and increased graft vs host disease (GVHD) remain obstacles to success for unrelated donor (URD) BMT for patients with SAA. Partial T cell depletion (PTCD) may decrease the risk of severe GVHD, while still maintaining sufficient donor T lymphocytes to ensure engraftment. We report on 12 patients with SAA who underwent PTCD URD BMT. All patients had failed medical therapy or relapsed following initial responses, and were transfusion dependent. The median age was 6 years, and there were five males. Donors were matched for four patients, and mismatched for eight. All patients received total body irradiation with either Ara-C or thiotepa and cyclophosphamide. PTCD was accomplished using monoclonal antibody T10B9 or OKT3 and complement. All patients engrafted, with a median time of 18 days to ANC 4500. Only one patient had greater than grade II acute GVHD; two patients had limited and one patient extensive chronic GVHD. Nine patients are alive and transfusion independent at a median months post BMT. Three patients died from infection or renal failure. This series suggests that an aggressive immunosuppressive conditioning regimen with PTCD results in successful engraftment and minimal GVHD in pediatric patients with SAA, even with HLA mismatched donors.
donor Allogeneic stem cell transplantation (SCT) is curative therapy for patients with SAA. Survival following a matched sibling donor (MSD) bone marrow transplant with young patients is 485%. [1] [2] [3] [4] Most of these patients undergo SCT soon after diagnosis, and have been minimally transfused. Conditioning therapy for these patients is immunosuppressive, rather than myeloablative, and durable engraftment occurs promptly.
For patients who lack an MSD, medical therapy with immunosuppressive agents such as anti-thymocyte globulin (ATG), cyclosporine, corticosteroids, and hematopoietic growth factors is the recommended therapy. Up to 80% of patients respond to immunosuppressive therapy, 5 with sustained responses in 40-50%. However, for patients who fail to respond, or achieve a sustained response, alternative donor SCT is an option for achieving normal hematopoiesis. Results with alternative donors, including unrelated or partially matched related donors, have been inferior to MSD BMT. 6, 7 Multiple transfusions, with possible alloimmunization, increase the risk of graft rejection, and graft vs host disease (GVHD) risks are significantly higher with alternative donors. T cell depletion (TCD) may reduce the risk of GVHD, but has been associated with increased risks of graft rejection. However, partial T cell depletion (PTCD), which maintains sufficient donor lymphocytes to overcome host resistance, in combination with increased pre-BMT immunosuppression, may allow engraftment without the risks of severe GVHD. We report on 12 pediatric patients with SAA who underwent unrelated donor BMT with PTCD. In a majority of patients, the donors were HLA mismatched, but PTCD was successful in decreasing the risk of severe GVHD while allowing engraftment.
Patients and methods
These patients underwent BMT between 1992 and 2003. The study was approved by the Institutional Review Board, and informed consent was given for the transplant study by parents or patients, if X18 years old. Patients were considered for alternative donor SCT if they failed to respond to medical therapy with ATG, cyclosporine, and G-CSF, or relapsed following initial responses. Patients did not have HLA matched, or 5/6 matched related donors.
Donors and histocompatibility methods
Donors were located through the National Marrow Donor Program. Donors and patients were analyzed by high-resolution typing at DRB1 and DQB1. Following 1997, typing of class I antigens was performed by DNA-based intermediate resolution methods including sequence-specific oligonucleotide probes or sequence-specific primer. 8 
Transplantation procedures
All patients were transplanted in HEPA-filtered private rooms. Infectious prophylaxis included oral antibiotics, acyclovir, cotrimazole until day À1, followed by Pentamidine until engraftment, and intravenous gammaglobulin 400 mg/kg every other week. Patients who were CMV seropositive, or who had CMV seropositive donors were screened for CMV reactivation after 2000 by quantitative antigenemia. Ganciclovir or foscarnet was initiated for any evidence of reactivation.
Conditioning initially included cytosine arabinoside 3 g/ m 2 q 12 h Â 4 doses, days À7, À6; cyclophosphamide 45 mg/ kg Â 2, days À5, À4; and total body irradiation (TBI) 1320 cGy in six fractions. The subsequent protocol included thiotepa 5 mg/kg, days À6, À5 (total 10 mg/kg); cyclophosphamide 60 mg/kg, days À4, À3 (total, 120 mg/kg); and TBI 1200 cGy in six fractions. Thymoglobulin (Sangstat, Fremont, CA, USA) was given to the last seven patients at 1.5 mg/kg, days -2, À1, 0. Four of these patients were given Thymoglobulin for additional GVHD prophylaxis; three had mismatched donors, and four received OKT3-depleted bone marrow. Cyclosporine (CSA) was given intravenously starting on day À1, and oral CSA or tacrolimus continued as an outpatient. Weaning was commenced in the absence of GVHD at 100 days. All CSA was discontinued by 150 days, unless there was chronic GVHD. GVHD was defined using conventional criteria. 9 Engraftment was defined as the first of 3 days of neutrophils 4500 Â 10 9 /l. Chimerism studies were performed using fluorescent in situ hybridization if sex mismatched donor, or variable nucleotide tandem repeats.
PTCD
The bone marrow was initially concentrated and partially red cell depleted on the COBE 2991 blood processor (Cobe BCT, Inc., Lakewood, CO, USA). The bone marrow mononuclear fraction was T cell depleted with monoclonal antibody (Mab) and complement (C-six Diagnostics, Germantown, WI, USA) at a final cell concentration of 15 Â 10 6 /ml. The antibody initially used was T10B9. However, since we were unable to obtain this antibody in a form suitable under FDA guidelines, OKT3 (Muromonoab, Ortho Biotech, Raritan, NJ, USA) was substituted in 2000. The mononuclear cells were first incubated with the antibody at 2À61C on a rotator for 30 min. After the antibody incubation, DNAse (Sigma, St Louis, MO, USA) was added at 50 U/ml and young rabbit complement added at concentrations ranging from 35 to 50% for 90 min at 371C with gentle agitation on an Orbitron Rotator. The complement lots were prescreened in a small-scale Tdepletion test for activity and lack of toxicity to progenitor cells. The cells were washed on the COBE processor with Lactate Ringer's and human serum albumin (has). Before the last two washes, a 5 min incubation with DNAse at 371C was included to break up any clumps. For the infusion, the cells were resuspended in Lactated Ringer's and HSA. Quality control assays included cell counts and differentials at various steps in the processing, bacterial and fungal cultures, and flow cytometric analysis before and after TCD. Flow evaluation for CD34 þ and a T cell panel was performed initially with indirectly conjugated Mab, and later with directly conjugated Mab.
Statistical analysis
Clinical data were collected prospectively and entered into a MS Access Database. The Kaplan-Meier method was used to describe survival. STATA 8.0 was used for the statistical analysis.
Results
Clinical and transplant features of these patients are shown in Table 1 . One patient had Schwachman-Diamond syndrome; SAA was idiopathic in the other 11 patients. Eight patients failed to respond to initial therapy, and four patients had initial responses, but subsequently relapsed. All patients were red cell and platelet dependent prior to BMT, and had received 420 transfusions. The median cell dose after TCD was 1.1 Â In vitro T cell depletion T10B9 8 OKT3 4
Unrelated donor T cell-depleted BMT for children with SAA N Bunin et al become transfusion independent. Chimerism studies performed on days 30-45 post BMT demonstrated 496% donor engraftment. Nine patients (75%) are alive 13 þ to 153 þ months post BMT (Figure 1 ). Eight patients have activity scores of 100 and one has a score of 90. Acute GVHD grades I-II developed in three patients, and grade III in one. Two patients developed limited chronic GVHD, and one patient extensive skin involvement.
Morbidity included severe veno-occlusive disease in a patient with Schwachman-Diamond syndrome, who subsequently underwent successful related donor liver transplant. 10 One patient developed autoimmune hemolytic anemia at 12 months, which resolved with steroid therapy, and has been reported as a complication of T-depleted BMT.
11 CMV reactivation by antigenemia testing occurred in three patients. One died at day þ 165 of CMV, despite therapy with ganciclovir and foscarnet, and one has visual loss from CMV retinitis. Two other deaths occurred at days 237 and 282 from renal failure and PCP, respectively. Delayed T lymphocyte recovery at 12 months was apparent in six patients for whom this information was available. Median CD4 þ was 14 (8.5-32.9) and median CD8 þ was 21.6 (15.7-65.9). The CD4 þ /CD8 þ was o1 in all but one patient, in whom it was 1.1. IgG levels were normal in all patients by 12 months.
Discussion
Children with SAA with MSD achieve results of 495% survival with bone marrow transplantation.
12,13,4 Successful engraftment does not require the use of radiation, thereby decreasing the risk of radiation sequelae.
14,2 For patients who lack an MSD, immunosuppressive therapy achieves responses in up to 80%, but problems include cyclosporine dependence, and poor compliance due to side effects, clonal evolution, relapse of aplasia, and poor responses necessitating transfusions. Up to 36% of responding patients may relapse at 2 years, 15 and although many patients may be retreated successfully, the quality of life may suffer. A comparison between recipients of MSD BMT noted 97% EFS at 10 years, in contrast to 40% EFS for patients who received immunosuppressive therapy. 16 The addition of G-CSF may increase the risk of clonal abnormalities without improving survival. Myelodysplastic syndromes have been reported in 20% of patients treated for long periods with G-CSF and cyclosporine with colony-stimulating factors. 17, 18 Unrelated donor BMT for SAA has resulted in inferior outcomes compared to MSD BMT. 6, 7, 19 Contributing factors for this include the increased duration between diagnosis and BMT, with chronic transfusions and risk of alloimmunization, or infections in neutropenic patients. Graft rejection and GVHD account for significant morbidity and mortality in these patients. 19 In the study by Davies et al, 20 seven SAA children underwent BMT with URD; three survived, and grades III-IV acute GVHD were 37% with T-replete bone marrow. The series from Japan noted 11% early or late rejection, with grades III-IV acute GVHD 20%, and chronic GVHD 30%. Mismatching was an unfavorable feature on multivariate analyis. 7 In a separate pediatric study, this same group noted 33% severe GVHD. 21 Our results compare favorably to other series of pediatric BMT for SAA using URD. Margolis et al 22 reported 55% survival at 33 months with a similar approach, but graft rejection was higher in mismatched recipients. Vassilou et al 23 used a novel approach with in vivo Campath, cyclophosphamide, and low-dose TBI, at 300 cGy for a single fraction. Cyclosporine and methotrexate were used for patients who received Campath-1G, but methotrexate was not given with Campath-1H. All patients were matched by low resolution, and all engrafted. No patients developed severe GVHD or chronic GVHD. This approach may decrease sequelae, with decreased dose of TBI, and the Campath may reduce the risk of GVHD, but this protocol has not been evaluated in mismatched patients. Recent studies with large doses of CD34 þ selected unrelated donor or partially matched related donor peripheral stem cells for patients who lack a compatible related donor look encouraging, 24 although three patients with haploidentical donors required additional infusions. 25 Both graft failure and GVHD are associated with serologic mismatched donors. 26, 27 Some studies have suggested that children tolerate HLA disparity better than older patients, even in the T-replete setting. 28, 27 Although improved matching by high-resolution typing at all loci may improve survival in the T-replete setting, it may be less important with PTCD and will limit donor availability. This may be particularly important for minority patients in which a complete match is more difficult to find. Of note, eight of our patients were minorities (two, Asian, six African American), and six received mismatched grafts.
TCD of the unrelated donor graft is an effective means of decreasing the risk of GVHD, but it has been associated with an increase in graft rejection and delay in immune reconstitution. 29 The risk of rejection is dependent upon the method and degree of TCD, as well as the intensity of conditioning. Graft rejection has been associated with extensive TCD, with a 3 log or greater reduction. This may be overcome with increased immunosuppression with post BMT ATG. 30 While post transplant immunosuppression is not required with more complete TCD, the increased immunosuppression with ATG may increase the risk of EBV lymphomas. A 99% TCD corresponds to approximately 1 Â 10 5 /kg T cells 31 and the median amount our patients received was 1 log greater. Partial TCD does require additional immunosuppression post BMT, but in the absence of GVHD can be rapidly weaned. Immune reconstitution was significantly delayed with partial TCD, with subnormal CD4 þ and CD8 þ . This persistent deficiency of CMV-specific CD8 þ cytotoxic T lymphocytes may have increased the risk of CMV disease, 32 despite appropriate antibiotic therapy.
Engraftment is a large barrier to success in patients receiving URD BMT for SAA. In the series by Margolis et al 22 in which partial TCD was used, there was a 15% incidence of graft rejection in mismatched patients without post transplant ATG. However, the risk of post-BMT ATG resulted in the development of EBV LPD in 2/8 patients. Both ATG and ALG have long half-lives, but may delay immune recovery and increase the risk of viral infections. 33 We elected to use ALG only pre-BMT, and none of our patients developed EBV LPD. Other methods to ensure engraftment include escalation of TBI dose or chemotherapy added to cyclophosphamide. 34 However, the majority of our patients received only 1200 cGy, and all engrafted. Therefore, it was not essential to expose children to increased risks of organ toxicity from higher doses. Immunosuppressive drugs, such as cytarabine and thiotepa, may facilitate engraftment as well. 35, 36 It would be ideal to avoid irradiation altogether for these young patients, due to effects upon growth, organ development, and increased risk of secondary cancers. 37, 38 Although chemotherapy-only regimens appear successful in achieving engraftment in SAA patients receiving MSD, irradiation may be necessary for URD or partially matched related donor recipients. 39, 40 A recent study by the NMDP studied de-escalation of TBI in conjunction with ATG and cyclophosphamide 19 in patients with SAA. As little as 200 cGy resulted in engraftment in some patients, but this was T-replete marrow, and these results may not be applicable to Tdepleted grafts. However, lower doses of TBI, in conjunction with drugs such as fludarabine, may be successful in achieving engraftment in patients with SAA.
Early referral and identification of a suitable donor is important for patients with SAA who lack an MSD and who do not respond adequately to medical therapy. If the first course of therapy does not result in remission, then a second course may be given while donor search is initiated. Partial TCD allows the use of both matched and mismatched unrelated donors for young patients with refractory SAA, with limited GVHD and durable engraftment.
